Eleniak Shane Todd Marshall 4
4 · CALIX, INC · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Calix (CALX) CPO Shane Eleniak Receives 195,000-Share Option Award
What Happened Shane Eleniak, Chief Product Officer of Calix, reported the acquisition of a 195,000-share derivative (performance-based stock option) on Feb 12, 2026. The transaction is recorded at $0.00 per share because this filing reflects the grant/vesting of a performance-based option rather than a cash purchase. No sale or exercise-for-cash is reported in this transaction.
Key Details
- Transaction date: February 12, 2026; Report filed: February 17, 2026.
- Transaction type/code: A — Grant/Award/Acquisition of a derivative (performance-based option).
- Shares involved: 195,000 options; Reported price: $0.00 (derivative acquisition).
- Shares owned after transaction: Not specified in the provided summary—see the official Form 4 for post-transaction holdings.
- Footnote summary: The option was originally granted Jan 31, 2025. On Feb 12, 2026 the Compensation Committee certified that performance criteria for 100% of the grant were met. Vesting: 25% vested Jan 31, 2026; remaining 75% vest quarterly in equal installments over 36 months beginning Jan 31, 2026, subject to continued employment.
- Filing timeliness: Form 4 lists the filing date (Feb 17, 2026) for the Feb 12 transaction — consult the official filing for any timeliness designation.
Context This filing documents a performance-based option vesting (a derivative award), not a cash exercise or sale. Vesting does not necessarily mean shares were exercised into common stock or sold—those would generate separate filings if they occur. Performance-based vesting is a common form of executive compensation and does not by itself indicate a buy or sell signal.
Insider Transaction Report
- Award
Stock Option
[F1]2026-02-12+195,000→ 195,000 totalExercise: $39.68From: 2026-01-31Exp: 2035-01-31→ Common Stock (195,000 underlying)
Footnotes (1)
- [F1]On January 31, 2025, the reporting person was granted a performance-based option to purchase 195,000 shares of common stock. On February 12, 2026, the Compensation Committee determined that the performance criteria governing 100% of the grant had been achieved. The option vests: (i) as to 25% of the shares of common stock subject to the stock option, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from January 31, 2026, subject to continued employment with Calix through the applicable vesting dates.